跳轉至內容
Merck
  • Comparison of two Gram stain point-of-care systems for urogenital gonorrhoea among high-risk patients: diagnostic accuracy and cost-effectiveness before and after changing the screening algorithm at an STI clinic in Amsterdam.

Comparison of two Gram stain point-of-care systems for urogenital gonorrhoea among high-risk patients: diagnostic accuracy and cost-effectiveness before and after changing the screening algorithm at an STI clinic in Amsterdam.

Sexually transmitted infections (2014-05-27)
M Bartelsman, M Straetemans, K Vaughan, S Alba, M S van Rooijen, W R Faber, H J C de Vries
摘要

To compare point-of-care (POC) systems in two different periods: (1) before 2010 when all high-risk patients were offered POC management for urogenital gonorrhoea by Gram stain examination; and (2) after 2010 when only those with symptoms were offered Gram stain examination. Retrospective comparison of a Gram stain POC system to all high-risk patients (2008-2009) with only those with urogenital symptoms (2010-2011) on diagnostic accuracy, loss to follow-up, presumptively and correctly treated infections and diagnostic costs. Culture was the reference diagnostic method. In men the sensitivity of the Gram stain was 95.9% (95% CI 93.1% to 97.8%) in 2008-2009 and 95.4% (95% CI 93.7% to 96.8%) in 2010-2011, and in women the sensitivity was 32.0% (95% CI 19.5% to 46.7%) and 23.1% (95% CI 16.1% to 31.3%), respectively. In both periods the overall specificity was high (99.9% (95% CI 99.8% to 100%) and 99.8% (95% CI 99.7% to 99.9%), respectively). The positive predictive value (PPV) and negative predictive value (NPV) before and after 2010 were also high: PPV 97.0% (95% CI 94.5% to 98.5%) and 97.7% (95% CI 96.3% to 98.6%), respectively; NPV 99.6% (95% CI 99.4% to 99.7%) and 98.8% (95% CI 98.5% to 99.0%), respectively. There were no differences between the two time periods in loss to follow-up (7.1% vs 7.0%). Offering Gram stains only to symptomatic high-risk patients as opposed to all high-risk patients saved €2.34 per correctly managed consultation (a reduction of 7.7%). The sensitivity of the Gram stain is high in men but low in women. When offered only to high-risk patients with urogenital symptoms, the cost per correctly managed consultation is reduced by 7.7% without a significant difference in accuracy and loss to follow-up.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
结晶紫溶液 溶液, 1%, aqueous solution
Sigma-Aldrich
结晶紫, certified by the Biological Stain Commission
Sigma-Aldrich
结晶紫, ACS reagent, ≥90.0% anhydrous basis
Sigma-Aldrich
结晶紫溶液 溶液
Sigma-Aldrich
阿齐霉素
Sigma-Aldrich
头孢曲松 二钠盐 半(七水合物), third-generation cephalosporin antibiotic
Sigma-Aldrich
结晶紫溶液 溶液
USP
阿齐霉素, United States Pharmacopeia (USP) Reference Standard
USP
头孢曲松 二钠盐 半(七水合物), United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
阿齐霉素 二水合物, ≥98% (HPLC)
Sigma-Aldrich
结晶紫, for microscopy (Bact., Bot., Hist., Vit.), indicator (pH 0.1-2.0)
Supelco
阿齐霉素, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
结晶紫, VETRANAL®, analytical standard
Supelco
头孢曲松钠, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
龙胆紫, meets USP testing specifications
USP
鉴定用阿奇霉素, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
结晶紫, indicator for the determination of the redox potential, S. No.: 785
阿奇霉素, European Pharmacopoeia (EP) Reference Standard
头孢曲松 二钠盐 半(七水合物), European Pharmacopoeia (EP) Reference Standard
阿齐霉素 二水合物, European Pharmacopoeia (EP) Reference Standard
结晶紫, European Pharmacopoeia (EP) Reference Standard
结晶紫, European Pharmacopoeia (EP) Reference Standard
阿齐霉素 二水合物, European Pharmacopoeia (EP) Reference Standard